H&S Research Search

What do you remember?

Try a workplace, company, occupation, product, city, trust, or another detail you remember.

Start with one remembered detail.

Your search stays in your browser. Nothing you type here is submitted to H&S. Open full search →
Mesothelioma News | Treatment and immunotherapy research

Why Does Immunotherapy Work for Some Mesothelioma Patients? New Study Examines Immune Cells Inside Tumors

A new study explores why some pleural mesothelioma tumors respond to immunotherapy, and why the findings cannot yet predict individual outcomes.

Published November 20, 2026 · H&S Research & News Desk

← Back to Mesothelioma News

Why do some people with pleural mesothelioma respond to immunotherapy while others receive little benefit?

A new study published November 20, 2026, offers evidence that the answer may depend partly on the immune cells already present inside and around a patient's tumor.

Researchers at Oslo University Hospital and collaborating American institutions studied tumor tissue from people with pleural mesothelioma who received nivolumab and ipilimumab, two drugs that help the immune system recognize and attack cancer.

They found that tumors with stronger signs of immune activity were more likely to respond to treatment.

The study also identified changes in immune activity during the early weeks of treatment.

These findings do not establish a new treatment, a validated predictive test, or a change to current mesothelioma treatment recommendations.

Why immunotherapy does not work equally well for everyone

Nivolumab and ipilimumab are immune-checkpoint inhibitors.

Rather than attacking cancer cells directly in the way traditional chemotherapy does, they interfere with signals that can prevent immune cells from mounting an effective response against cancer.

The combination has become an established treatment option for certain patients with unresectable pleural mesothelioma.

However, not every patient experiences tumor shrinkage or lasting disease control.

For an overview of current care, see our mesothelioma treatment guide. Researchers are therefore investigating whether characteristics of a tumor can help explain which patients are most likely to benefit.

Our earlier MTAP research report examines a different potential marker of immunotherapy response. One area of interest is the tumor microenvironment—the mixture of immune cells, connective tissue, blood vessels and other surrounding components that interact with cancer cells.

What did the new study examine?

The researchers analyzed tumor specimens from patients participating in the NIPU clinical trial.

That earlier trial investigated nivolumab and ipilimumab, with or without an experimental telomerase vaccine called UV1, in patients whose pleural mesothelioma had progressed after platinum-based chemotherapy.

The November 20 publication reports a separate analysis of patients enrolled at the Oslo study center.

The researchers examined tumor biopsies obtained before immunotherapy and again approximately five weeks after treatment began.

They successfully performed RNA sequencing on 31 pretreatment specimens and 23 specimens collected during treatment. Seventeen patients had usable specimens from both time points.

RNA sequencing allowed the researchers to examine patterns of gene activity associated with immune cells and surrounding tissue.

The objective was to determine whether those patterns were related to the patients' responses to treatment.

What did researchers discover?

The investigators identified two broad patterns.

Some tumors contained stronger evidence of immune-cell activity and relatively less stromal tissue, the structural and connective tissue surrounding cancer cells.

Other tumors showed comparatively more stromal activity and less evidence of effective immune involvement.

Among the five patients who experienced partial tumor responses and had usable pretreatment tissue profiles, four belonged to the immune-enriched group.

The investigators also found increased activity in biological pathways associated with inflammation and interferon signaling among patients whose tumors responded.

Interferons are signaling proteins involved in coordinating immune responses.

The findings suggest an association between an already active immune environment and response to checkpoint inhibitors, but do not establish causation.

However, the relationship was not absolute. Some tumors with apparently favorable immune characteristics did not respond, and the sample was too small to establish a reliable prediction rule.

Can these findings predict which patients will benefit?

Not yet.

The researchers evaluated a four-gene inflammatory signature involving CD8A, STAT1, LAG3 and CD274, along with other measures of immune and stromal activity.

These measurements were associated with tumor response in the exploratory analysis.

But neither the pretreatment immune score nor the four-gene signature demonstrated a statistically significant association with overall survival.

The study also included relatively few patients whose tumors shrank, and the findings require confirmation in larger, independent groups.

That distinction is important.

A biological measurement may be associated with treatment response in research without being sufficiently accurate to guide decisions for individual patients.

The November 20 study does not establish that patients should receive or be denied immunotherapy based on these gene-expression patterns.

What happened after treatment began?

The investigators also examined changes in tumor tissue during the first five weeks of immunotherapy.

In many patients, the estimated immune-cell activity increased or remained relatively stable.

One patient provided an especially interesting example.

Although the tumor initially appeared relatively poor in immune-cell involvement, the follow-up biopsy showed increased activity from several immune-cell populations.

The patient subsequently experienced a partial and sustained tumor response.

The researchers described this as a possible example of treatment changing the immune environment within a tumor.

However, it was an observation involving one patient and cannot establish how frequently this occurs or whether the observed immune changes caused the response.

Did the study demonstrate that the UV1 vaccine works?

No.

The biopsy investigation used patients from the earlier NIPU trial, which compared nivolumab and ipilimumab with and without the experimental UV1 vaccine.

The original randomized trial did not meet its primary endpoint of improving progression-free survival as assessed by blinded independent central review.

The new analysis was designed to investigate immune-cell and gene-expression patterns—not to establish that UV1 improves survival.

The investigators did not identify a statistically significant difference between the treatment groups in the changes to the principal immune-cell measurements examined.

UV1 remains an investigational approach, not an established mesothelioma treatment.

What does this mean for mesothelioma patients now?

For patients currently receiving or considering immunotherapy, the study does not require a change in care.

The choice of treatment still depends on the individual's diagnosis, histological subtype, previous treatments, overall health, medical circumstances and preferences.

Researchers hope that future studies will identify biomarkers that can help physicians determine which patients are most likely to benefit from particular treatments.

If reliable tests eventually become available, they could help patients avoid ineffective treatment or identify more promising options.

But no such test has been validated by this study.

Our mesothelioma specialist resource provides additional guidance. Patients may wish to ask their treating oncologists how treatment response will be evaluated, what the next steps would be if immunotherapy does not control the disease, and whether a clinical trial is appropriate.

Why this research matters

One of the greatest challenges in treating mesothelioma is the difference between patients who benefit from immunotherapy and those who do not.

The November 20 study adds evidence that the immune environment surrounding a tumor may be part of the explanation.

It also demonstrates why research needs to examine more than a single gene or laboratory marker.

The relationship between cancer cells, immune cells and surrounding tissue is complex and may change during treatment.

The next challenge is determining whether these observations can be reproduced in larger patient populations and developed into tests that meaningfully improve treatment decisions.

For now, this is progress in understanding mesothelioma biology—not proof of a new treatment benefit.

Original research and authoritative sources

Thunold and colleagues — Frontiers in Immunology, November 20, 2026

Medical information notice: This article reports exploratory medical research for educational purposes. The reported associations are not validated clinical tests and do not establish that an individual patient will respond to immunotherapy. Patients should not begin, discontinue or change treatment based on these findings without consulting their oncology team. Humpleby & Strauss, P.C. is a law firm and does not provide medical diagnosis or treatment.

Explore more Mesothelioma News and Court Developments